Because this was not a formal study with controlled
variables, it is impossible to assess how much
HFCWO contributed to the clinical improvement
and concurrent functional and quality of life gains
experienced by the patient described in this report.
However, prior to beginning HFCWO airway
clearance therapy, this patient’s pulmonary function,
physical stamina, emotional health, and quality of
life were uniformly poor and declining rapidly. The
Vest™ system was the significant variable in her
treatment, and the qualitative improvements in her
respiratory and physical status are evidenced by
sharply reduced dyspnea. In addition to sustained
gains in her general health, including freedom from
pulmonary infections and increased respiratory
stamina, the patient’s symptoms of anxiety, extreme
fatigue, and depression subsided; her level of
physical and social activity increased remarkably.
This case suggests that further study is indicated
concerning the role of HFCWO in the maintenance
and rehabilitation of COPD patients with significant
mucus hypersecretion.